Joseph Spirito, MD
Internal Medicine · Fall River, MANPI 1790775963
Payments from drug & device makers
Across 231 payments — averaging $20.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$799
- Alkermes, Inc.$444
- Indivior Inc.$421
- AbbVie$419
- Lilly USA, LLC$380
- Novo Nordisk$251
- plus $2K from 28 others
What the payments were for
- Food & beverage$4,76299%
- Education$421%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 37 | $799 |
| Alkermes, Inc. | 22 | $444 |
| Indivior Inc. | 21 | $421 |
| AbbVie(2 entities) | 18 | $419 |
| Lilly USA, LLC | 18 | $380 |
| Novo Nordisk | 13 | $251 |
| Pfizer | 10 | $199 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 11 | $193 |
| Boehringer Ingelheim | 3 | $167 |
| Exact Sciences | 7 | $157 |
| Abbott | 7 | $152 |
| Novartis | 7 | $126 |
| E.r. Squibb & Sons, L.L.C. | 4 | $104 |
| Otsuka America Pharmaceutical, Inc. | 5 | $104 |
| Bayer | 5 | $101 |
| Nestle Healthcare Nutrition Inc. | 4 | $86 |
| Lundbeck LLC | 3 | $85 |
| Takeda Pharmaceuticals U.S.A., Inc. | 7 | $76 |
| Johnson & Johnson | 5 | $73 |
| GSK | 3 | $67 |
| Phathom Pharmaceuticals, Inc. | 2 | $44 |
| Corcept Therapeutics | 2 | $44 |
| Braeburn Inc. | 2 | $39 |
| Paratek Pharmaceuticals, Inc. | 2 | $39 |
| Biogen | 2 | $34 |
| Mylan Specialty L.p. | 2 | $34 |
| Melinta Therapeutics, LLC | 2 | $31 |
| Viatris Specialty LLC | 1 | $29 |
| Alnylam Pharmaceuticals Inc. | 1 | $23 |
| Xeris Pharmaceuticals, Inc. | 1 | $20 |
| Eisai Inc. | 1 | $20 |
| Orexo US, Inc. | 1 | $20 |
| Idorsia Pharmaceuticals US Inc | 1 | $16 |
| Kowa Pharmaceuticals America, Inc. | 1 | $12 |
How this compares
$4,805 in reported general payments places this provider in the 90th percentile of 4,983 internal medicine providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 240 | $142,760 |
| IngrezzaValbenazine Tosylate | 15 | $107,825 |
| XifaxanRifaximin | 32 | $40,895 |
| VivitrolNaltrexone Microspheres | 21 | $34,144 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 48 | $31,037 |
| OzempicSemaglutide | 22 | $28,840 |
| FarxigaDapagliflozin Propanediol | 47 | $28,454 |
| Naproxen-Esomeprazole MagNaproxen/Esomeprazole Mag | 14 | $25,470 |
| TrulicityDulaglutide | 21 | $19,485 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 148 | $18,451 |
| JardianceEmpagliflozin | 21 | $18,420 |
| JanuviaSitagliptin Phosphate | 25 | $16,969 |
| LinzessLinaclotide | 24 | $12,897 |
| Xtampza ErOxycodone Myristate | 14 | $8,124 |
| BelsomraSuvorexant | 11 | $4,848 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $199 | $142,760240 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan | $193 | $40,89532 claims |
| Alkermes, Inc.Vivitrol | $444 | $34,14421 claims |
| GSKTrelegy Ellipta | $67 | $31,03748 claims |
| Novo NordiskOzempic | $251 | $28,84022 claims |
| AstraZenecaFarxiga | $799 | $28,45447 claims |
| Lilly USA, LLCTrulicity | $380 | $19,48521 claims |
| Boehringer IngelheimJardiance | $167 | $18,42021 claims |
| AbbVieLinzess | $419 | $12,89724 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,983 internal medicine providers in Massachusetts.
Other internal medicine in Fall River
- Ehab SorialFall River$2.5M
- Noopur RajeBoston$19.9M
- Michael McCartneyNewburyport$17.6M
- Rebecca HeistBoston$17.4M
- Richard PlattBoston$13.5M
- Ryan CorcoranBoston$11.4M
- Joyce LiuCharlestown$10.3M
- Elizabeth LeeBoston$9.8M
- Adnan DahdulSpringfield$8.8M
- Ryan SullivanCambridge$8.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.